Date:5/15/2012

in a timely manner, GeoVax's vaccines will be safe for human use, GeoVax's vaccines will effectively prevent AIDS in humans, vaccines will receive regulatory approvals necessary to be licensed and marketed, GeoVax raises required capital to complete vaccine development, there is development of competitive products that may be more effective, less costly, or easier to use than GeoVax's products, GeoVax will be able to enter into favorable manufacturing and distribution agreements, and other factors, over which GeoVax has no control. GeoVax assumes no obligation to update these forward-looking statements, and does not intend to do so. More information about these factors is contained in GeoVax's filings with the Securities and Exchange Commission including those set forth at "Risk Factors" in GeoVax's Form 10-K.

Contact
The Investor Relations Group:
Erika Moran, Investor Relations
Janet Vasquez, Public Relations
(212) 825-3210

FINANCIAL TABLES FOLLOWGEOVAX LABS, INC.Condensed Consolidated Statements of Operations Information(amounts in thousands, except per share data)Three Months EndedMarch 31, 2012

2011RevenuesGrant Revenue$
854

$
893Operating expenses:Research and development1,072

838General and administrative513

6621,585

1,500Other income:Interest income1

11

1Net loss$
(730)

$
(606)Loss per common share$  (0.04)

$
(0.04) GEOVAX LABS, INC.Condensed Balance Sheet Information(amounts in thousands)March 31,

Dec. 31,2012

2011Assets:Cash and cash equivalents$
2,240

$
,168Other current assets393

250Total current assets2,633

1,418Property, net 158

176Other assets46

51Total assets$
2,837

$
,645Liabilities and stockholders' equityCurrent liabilities$
510

$
941Stockholders' equity2,327

704Total liabilities and stockho
'/>"/>

SOURCE GeoVax Labs, Inc. Copyright©2010 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5 6
Related medicine technology :

1. GeoVax Labs CEO Update Letter to Shareholders
2. GeoVax Labs First Patient Inoculated in Phase 1/2 Clinical Trial for HIV/AIDS Therapeutic Vaccine
3. GeoVax Phase 2a Clinical Trial Completes Enrollment
4. GeoVax $3.6 Million Award Increased to $4.4 Million by U.S. Government
5. GeoVax Labs, Inc. Announces Second Quarter Financial Results
6. GeoVax Labs HIV/AIDS Vaccine Development Leadership to be Highlighted During 2011 World Vaccine Congress
7. GeoVax Announces Publication of Phase 1 Clinical Trial in The Journal of Infectious Diseases
8. GeoVax Launches a Second Clinical Site to Test the Therapeutic Benefit of its HIV Vaccine
9. David A. Dodd Appointed Chairman of the Board of GeoVax Labs
10. GeoVax Announces Expansion of Phase 2a Human HIV/AIDS Vaccine Trial
11. GeoVax Awarded Federal Grant Under the Qualifying Therapeutic Discovery Project Program